NeOnc Technologies Schedules FDA End-of-Phase 1 Meeting for NEO212

What Happened
NeOnc Technologies Holdings, Inc. filed a Form 8-K on September 28, 2026 announcing it will meet in person with the U.S. Food and Drug Administration for an End-of-Phase 1 Type B meeting about its drug candidate NEO212. The meeting is scheduled for November 17, 2026. The company also issued a press release about the meeting (furnished as Exhibit 99.1 to the 8-K).

Key Details

• Filing date: September 28, 2026 (Form 8-K, Regulation FD disclosure).
• FDA meeting: End-of-Phase 1 Type B, in-person, scheduled for November 17, 2026.
• Product: NEO212 (the subject of the regulatory meeting).
• Company disclosure: press release dated September 28, 2026 provided as Exhibit 99.1.

Why It Matters
An FDA End-of-Phase 1 Type B meeting is an important regulatory milestone that can clarify the agency’s expectations for further clinical development and potential next steps. For investors, this meeting could affect NEO212’s development timeline and regulatory strategy; the company may report outcomes or guidance after the meeting that could influence sentiment and valuation. Watch for follow-up disclosures or press releases summarizing the meeting results.